Synapse - Bone Marrow Transplant

Results (2969)

Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
Blood (2023)

Fulltext@MSK | Save

Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy

Meeting Abstract

Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial

Meeting Abstract

Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
Blood (2023)

Fulltext@MSK | Save

Post-Hoc analysis of measurable residual disease from BMT-CTN 1506/MORPHO: FLT3-ITD variant allele frequency and survival are highly correlated

Meeting Abstract

Levis, M. J.; Hamadani, M.; Logan, B. R.; Jones, R. J.; Singh, A. K.; Litzow, M. R.; Wingard, J. R.; Papadopoulos, E. B.; Perl, A.; Soiffer, R. J.; more...
Blood (2023)

Fulltext@MSK | Save

The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN study 1704

Meeting Abstract

Artz, A.; Logan, B. R.; Saber, W.; Geller, N.; Bellach, A.; Kou, J.; Wood, W.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
Blood (2023)

Fulltext@MSK | Save

Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3

Meeting Abstract

Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Costa, L.; Vij, R.; more...
Blood (2023)

Fulltext@MSK | Save

Improved overall survival with axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma among the elderly: A subgroup analysis of ZUMA-7

Meeting Abstract

Kersten, M. J.; Farooq, U.; Rapoport, A. P.; Locke, F. L.; Leslie, L. A.; Ghobadi, A.; Miklos, D. B.; Jacobson, C. A.; Munoz, J. L.; Johnston, P. B.; more...
Blood (2023)

Fulltext@MSK | Save

Ibrutinib added to standard conditioning and as consolidation therapy following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-b-cell subtype diffuse large B-cell lymphoma (ABC-DLBCL): Primary analysis of the US intergroup double-blind randomized phase III study alliance A051301/BMT-CTN 1201

Meeting Abstract

Andreadis, C.; Bobek, O.; Hsi, E. D.; Fenske, T. S.; Geyer, S. M.; Stiff, P. J.; Hill, B. T.; Horwitz, M.; Khimani, F.; Little, R. F.; more...
Blood (2023)

Fulltext@MSK | Save

Patient-reported outcomes of BMT CTN 1703: A randomized phase III study for GVHD prophylaxis - A quality of life evaluation

Meeting Abstract

Holtan, S. G.; Martens, M. J.; Al Malki, M. M.; Efebera, Y.; Kitko, C. L.; Reshef, R.; Rezvani, A. R.; Shaffer, B. C.; Solh, M. M.; Yao, J. M.; more...
Blood (2023)

Fulltext@MSK | Save

(131)I-apamistamab effectively achieved durable responses in patients with R/R AML irrespective of the presence of multiple high-risk factors

Meeting Abstract

Seropian, S.; Foran, J. M.; Gyurkocza, B.; Nath, R.; Choe, H.; Litzow, M. R.; Koshy, N.; Stiff, P. J.; Tomlinson, B. K.; Abhyankar, S.; more...
Blood (2023)

Fulltext@MSK | Save